Reported revenue dips to Rs 932 crore in the same quarter
Syngene International announced financial results for the third quarter of FY26.
Peter Bains, Managing Director and CEO, Syngene International, said, “Our Q3 performance reflects the ongoing impact related to a single product from one of our large-molecule biologics clients. Outside of this factor, the underlying business has shown steady progress, with Research Services securing new programs and delivering continued growth. The highlight of the quarter was the extension of our collaboration with Bristol Myers Squibb through to 2035. This extension provides both partners with a strategic ten-year horizon to further develop and expand this unique, long-standing collaboration.”
Deepak Jain, Chief Financial Officer, Syngene International Limited, said, “Despite the ongoing impact of a single customer, revenue has been flat QoQ, reflecting the underlying positive trend of the business.
